Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine
Open accessThe DOI matches its Crossref record.
Abstract
Serum carbohydrate antigen 19-9 (CA 19-9) has been identified as a useful tumour marker for diagnosis of exocrine pancreatic carcinoma, but its value for evaluating the response to chemotherapy with gemcitabine is not clear. Tumour regression in pancreatic carcinoma is hard to determine due to massive desmoplastic tissue. Furthermore, objective tumour response does not automatically transcribe into better survival. Therefore, clinical benefit response, a composed parameter consisting of factors like performance status, pain, and body weight was integrated in evaluating tumour response. The aim of this prospective study was to evaluate the usefulness of serial CA 19-9 measurements as a biochemical response marker and an outcome prognostic parameter in patients with advanced pancreatic cancer receiving gemcitabine treatment. A total of 46 consecutive patients (median age 66 years) suffering from histologically proven locally advanced or metastatic adenocarcinoma of the exocrine pancreas were analysed. Gemcitabine was applied for a median of 23 courses (range 6-76). Two patients achieved an objective complete remission, five an objective partial remission (overall response, OR=15.2%), while objective stable disease was documented in 19 and objective progressive disease in 20 patients. Patients with a decrease of >20% of the baseline CA 19-9 level after 8 weeks of chemotherapy had a significantly better median survival than patients with a rise or a decline <20%. The response of CA 19-9 >20% during chemotherapy was the only independent predictor of survival in a multivariate analyses. In contrast, neither objective tumour response nor clinical benefit response showed this level of significance. In conclusion, kinetics of CA19-9 serum concentration serves as an early indicator of response to gemcitabine chemotherapy in advanced pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
From carbohydrate leads to glycomimetic drugs
Ernst, B., & Magnani, J. L. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2852 · Cited by 820
Ballehaninna, U. K., & Chamberlain, R. S. (2012) · PubMed · doi:10.3978/j.issn.2078-6891.2011.021 · Cited by 701
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188409 · Cited by 446
Biology and management of pancreatic cancer
Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2008) · Postgraduate Medical Journal · doi:10.1136/gut.2006.103333 · Cited by 418
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report
Duffy, M. J., Sturgeon, C., Lamerz, R., Haglund, C., Holubec, V. L., Klapdor, R., Nicolini, A., Topolcan, O., & Heinemann, V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp332 · Cited by 381
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336
Hess, V., Glimelius, B., Grawe, P., Dietrich, D., Bodoky, G., Ruhstaller, T., Bajetta, E., Saletti, P., Figer, A., Scheithauer, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70001-9 · Cited by 239
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
Winter, J. M., Yeo, C. J., & Brody, J. R. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23192 · Cited by 234
“, improved survival, as expected) [41].”
O'Brien, D. P., Sandanayake, N. S., Jenkinson, C., Gentry-Maharaj, A., Apostolidou, S., Fourkala, E.-O., Camuzeaux, S., Blyuss, O., Gunu, R., Dawnay, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0365 · Cited by 200
“Despite this, CA19-9 has proved useful for disease management, in which increased posttherapy levels indicate poor prognosis and poor therapy response (16, 17).”
BackgroundBoeck, S., Stieber, P., Holdenrieder, S., Wilkowski, R., & Heinemann, V. (2006) · Oncology · doi:10.1159/000094888 · Cited by 172
“in 2000. These results (with the same definition of a CA 19-9 response) were confirmed by Ziske et al. [”
ResultPAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma
Gold, D. V., Karanjawala, Z., Modrak, D. E., Goldenberg, D. M., & Hruban, R. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1488 · Cited by 93
“The CA19-9 epitope, sialyl-Lea, could be associated with MUC1 (as well as several other mucins and glycolipids), and is considered the current biomarker of choice for the management of pancreatic cancer (30, 31).”
Background
Metadata
- Authors
- Ziske, C., Schlie, C., Gorschlüter, M., Glasmacher, A., Mey, U., Strehl, J., Sauerbruch, T., & Schmidt-Wolf, I. G. H.
- Venue
- British Journal of Cancer
- Published
- 2003-10
- Volume
- 89
- Issue
- 8
- Pages
- 1413-1417
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2039896904
- Cited by
- 167
- References
- 0
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.